Emin Evren Ozcan

Emin Evren Ozcan

Auto-generated profile, based on publicly available information

Emin Evren Ozcan

Department of Cardiology, Faculty of Medicine, Dokuz Eylül University, İzmir, Türkiye

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2007 in American Heart Journal
Verified
Journal Article
Closed access
EOEmin E. Ozcan
Emin E. Ozcan
SGSema Guneri
Sema Guneri
BABahri Akdeniz
Bahri Akdeniz
İAİlke Z. Akyıldız
İlke Z. Akyıldız
OSOmer Senaslan
Omer Senaslan
OBOzer Badak
Ozer Badak

13 June 2018 in EP Europace
Verified
Journal Article
Open access
PDF file
Giuseppe BorianiGiuseppe Boriani
Giuseppe Boriani
LFLaurent Fauchier
Laurent Fauchier
LALuis Aguinaga
Luis Aguinaga
JBJames M Beattie
James M Beattie
CLCarina Blomstrom Lundqvist
Carina Blomstrom Lundqvist
ACAshley Chin
Ashley Chin
Preamble 2 Evidence review 2Diagnosis of arrhythmias in the setting of intensive care units 3Arrhythmias in the critically ill and post-surgery patient: i

7 November 2014 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
VKValentina Kutyifa
Valentina Kutyifa
LGLaszlo Geller
Laszlo Geller
PBPeter Bogyi
Peter Bogyi
EZEndre Zima
Endre Zima
MAMehmet K. Aktas
Mehmet K. Aktas
BMBéla Merkely
Béla Merkely
Aims There are limited and contradictory data on the effects of CRT with implantable cardioverter defibrillator (CRT‐D) on mortality as compared with CRT with pacemaker (CRT‐P). Methods and results We evaluated the long‐term outcome of patients implanted with a CRT‐D or CRT‐P device in our high‐volume single‐centre experience. Data on all‐cause mortality were derived from clinic visits and the Hungarian National Healthcare Fund Death Registry. Kaplan–Meier survival analyses and multivariate Cox regression models were used to evaluate all‐cause mortality in patients with CRT‐D vs. CRT‐P, stratified by the aetiology of cardiomyopathy. From 2000 to 2011, 1122 CRT devices, 693 CRT‐P (LVEF 28.2 ± 7.4%) and 429 CRT‐D (LVEF 27.6 ± 6.4%), were implanted at our centre. During the median follow‐up of 28 months, 379 patients died from any cause, 250 patients (36%) with an implanted CRT‐P and 129 patients (30%) with an implanted CRT‐D. There was no evidence of mortality benefit in patients implanted with a CRT‐D compared with a CRT‐P in the total cohort [hazard ratio (HR) 0.98, 95% confidence interval (CI) 0.73–1.32, P = 0.884]. In patients with ischaemic cardiomyopathy, CRT‐D treatment was associated with a significant 30% risk reduction in all‐cause mortality compared with an implanted CRT‐P (HR 0.70, 95% CI 0.51–0.97, P = 0.03). In non‐ischaemic patients, there was no mortality benefit of CRT‐D over CRT‐P (HR 0.98, 95% CI 0.73–1.32, P = 0.894, interaction P‐value = 0.15). Conclusions In heart failure patients with ischaemic cardiomyopathy, CRT‐D was associated with a mortality benefit compared with CRT‐P, but no benefit of CRT‐D over CRT‐P in mortality was observed in non‐ischaemic cardiomyopathy.

11 December 2019 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
BGBulent Gorenek
Bulent Gorenek
JFJohn D. Fisher
John D. Fisher
GKGulmira Kudaiberdieva
Gulmira Kudaiberdieva
ABAdrian Baranchuk
Adrian Baranchuk
HBHaran Burri
Haran Burri
DLDhanunjaya Lakkireddy
Dhanunjaya Lakkireddy

25 January 2019 in EP Europace
Verified
Journal Article
Open access
PDF file
NSNándor Szegedi
Nándor Szegedi
GSGábor Széplaki
Gábor Széplaki
SHSzilvia Szív- és Érgyógyászati Herczeg
Szilvia Szív- és Érgyógyászati Herczeg
TTTamás Tahin
Tamás Tahin
ZSZoltán Salló
Zoltán Salló
LGLászló Gellér
László Gellér
Atrial fibrillation (AF) ablation has made huge progress with respect to innovation, efficacy, and safety, however, complications are still present. Recent studies examined various predictors of complications. However, limited data exist regarding the role of a repeat procedure. Our aim was the prospective evaluation of the incidence and predictors of complications related to AF ablation procedures in consecutive patients, including repeat procedures. All ablation procedures for AF between January 2013 and December 2015 were analysed in our electrophysiology laboratory. During the study period 1243 procedures were analysed [394 female, median age 62 (55–69)]. Overall complication rate was 6.84%, major complication rate was 2.82%. Major complications were the following: 18 pericardial tamponades; 5 pseudoaneurysms; 1 arteriovenous fistula; 6 thromboembolic cerebrovascular events; 3 pulmonary vein stenosis; and 2 atrioventricular blocks. No atrio-oesophageal fistula or procedure related death occurred. Univariate analysis for overall complications showed that age ≥ 65 years (P = 0.0231), female gender (P = 0.0438), hypertension (P = 0.0488), CHA2DS2-VASc score ≥ 2 (P = 0.0156), and previous AF ablation procedure (P < 0.0001) is associated with higher risk for adverse events. Multivariate analysis showed that the only independent predictor of overall complications was previous AF ablation procedure (P < 0.0001). Similarly, the only predictor of major complications was previous AF ablation procedure (P < 0.0001). Incidence of complications associated with AF ablation in our high volume electrophysiology laboratory is similar to other cohorts. The only independent predictor of complications was previous AF ablation procedure in our series.

6 June 2018 in Annals of Noninvasive Electrocardiology
Verified
Journal Article
Closed access
PDF file
TCTugce Colluoglu
Tugce Colluoglu
ZTZulkif Tanriverdi
Zulkif Tanriverdi
BUBaris Unal
Baris Unal
EOEmin Evren Ozcan
Emin Evren Ozcan
HDHuseyin Dursun
Huseyin Dursun
DKDayimi Kaya
Dayimi Kaya